Skip to main content

Table 1 Demographics and characteristics of patients at enrollment to therapy

From: Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States

 

LOT1 (n = 889)

 

LOT ≥ 2 (n = 605)

 

Characteristics

< 75 years

≥ 75 years

p valuea,b

< 75 years

≥ 75 years

p valuea,b

 

(n = 630)

(n = 259)

 

(n = 409)

(n = 196)

 

Age, years

 Mean

62.4

80.4

 

63.9

80.8

 

 SD

8.26

4.33

 

7.67

4.37

 

 Median

63.0

80.0

 

65.0

80.0

 

 Range

22–74

75–99

 

34–74

75–96

 

Sex, n (%)

 Male

411 (65.2)

155 (59.8)

0.1288

281 (68.7)

106 (54.1)

0.0005

 Female

219 (34.8)

104 (40.2)

 

128 (31.3)

90 (45.9)

 

Duration of CLL from diagnosis to registry enrollment, years

 Median

1.4

1.8

0.2912

7.0

7.2

0.7074

 Range

0–29

0–32

 

0–32

0–30

 

Time from diagnosis to first LOT, years

 Median

1.4

1.8

0.2593

1.4

2.3

0.0139

 Range

0–29

0–32

 

0–32

0–20

 

Race, n (%)c,d

 White

561 (92.3)

237 (92.9)

0.7211

352 (90.0)

183 (96.3)

0.0076

 Black

40 (6.6)

16 (6.3)

 

37 (9.5)

5 (2.6)

 

 American Indian/Alaskan native

0

0

 

1 (0.3)

0

 

 Asian

3 (0.5)

0

 

1 (0.3)

0

 

 Other

4 (0.7)

2 (0.8)

 

0

2 (1.1)

 

Geographic region, n (%)c,d

 Northeast

75 (12.0)

37 (14.3)

0.2029

58 (14.3)

37 (19.0)

0.016

 Midwest

207 (33.2)

70 (27.1)

 

137 (33.7)

45 (23.1)

 

 South

249 (40.0)

103 (39.9)

 

162 (39.8)

77 (39.5)

 

 West

92 (14.8)

48 (18.6)

 

50 (12.3)

36 (18.5)

 

Institution type, n (%)

 Academic

74 (11.7)

12 (4.6)

 

57 (13.9)

12 (6.1)

 

 Community

545 (86.5)

242 (93.4)

 

343 (83.9)

181 (92.3)

 

 Government

11 (1.7)

5 (1.9)

 

9 (2.2)

3 (1.5)

 

Insurance, n (%)e

 Medicare

283 (44.9)

229 (88.4)

 

227 (55.5)

175 (89.3)

 

 Medicaid

28 (4.4)

14 (5.4)

 

16 (3.9)

7 (3.6)

 

 Supplemental coverage

86 (13.7)

92 (35.5)

 

81 (19.8)

67 (34.2)

 

 Private coverage

357 (56.7)

46 (17.8)

 

189 (46.2)

35 (17.9)

 

  HMO

88 (14.0)

16 (6.2)

 

56 (13.7)

13 (6.6)

 

  PPO

206 (32.7)

26 (10.0)

 

103 (25.2)

14 (7.1)

 

  Other

64 (10.2)

4 (1.5)

 

33 (8.1)

8 (4.1)

 

 Military

10 (1.6)

5 (1.9)

 

5 (1.2)

6 (3.1)

 

 Self-pay

13 (2.1)

0

 

6 (1.5)

0

 

 Other Insurance

10 (1.6)

3 (1.2)

 

8 (2.0)

3 (1.5)

 

 Not specified

15 (2.4)

5 (1.9)

 

19 (4.6)

2 (1.0)

 

ECOG score and status, n (%)c,d

 0 - Fully active

276 (57.4)

70 (33.7)

<0.001

138 (46.8)

42 (30.7)

0.0105

 1 - Restricted in strenuous activity only

180 (37.4)

116 (55.8)

 

138 (46.8)

79 (57.7)

 

 2 - Ambulatory, but unable to work

22 (4.6)

19 (9.1)

 

17 (5.8)

14 (10.2)

 

 3 - Capable of only limited self-care

2 (0.4)

3 (1.4)

 

2 (0.7)

2 (1.5)

 

 4 - Completely disabled

1 (0.2)

0

 

0

0

 

Rai staging system score, n (%)c,d

 Stage 0

112 (23.7)

60 (28.4)

0.0219

63 (25.2)

46 (32.6)

0.1728

 Stage I

143 (30.2)

48 (22.7)

 

58 (23.2)

39 (27.7)

 

 Stage II

83 (17.5)

25 (11.8)

 

43 (17.2)

16 (11.3)

 

 Stage III

71 (15.0)

36 (17.1)

 

44 (17.6)

24 (17.0)

 

 Stage IV

64 (13.5)

42 (19.9)

 

42 (16.8)

16 (11.3)

 

Constitutional symptoms, n (%)

397 (63.0)

183 (71.8)

0.0192

264 (65.0)

126 (64.3)

0.977

 Fatiguef

328 (82.6)

152 (83.1)

 

212 (80.3)

114 (90.5)

 

 Fever

44 (11.1)

16 (8.7)

 

22 (8.3)

5 (4.0)

 

 Night sweats

164 (41.3)

62 (33.9)

 

85 (32.2)

27 (21.4)

 

 Other

69 (17.4)

44 (24.0)

 

54 (20.5)

25 (19.8)

 

 Weight loss

97 (24.4)

60 (32.8)

 

71 (26.9)

37 (29.4)

 

Metaphase cytogenetic analysis, n (%)e

 Yes

254 (40.3)

93 (35.9)

 

148 (36.2)

46 (23.5)

 

 Abnormalities foundf

110 (43.3)

48 (51.6)

 

81 (54.7)

23 (50.0)

 

  del(11q)

24 (9.4)

12 (12.9)

 

18 (12.2)

5 (10.9)

 

  del(13q)

36 (14.2)

11 (11.8)

 

23 (15.5)

7 (15.2)

 

  Trisomy 12

41 (16.1)

16 (17.2)

 

30 (20.3)

8 (17.4)

 

  del(17p)

13 (5.1)

6 (6.5)

 

12 (8.1)

3 (6.5)

 

  Other

35 (13.8)

18 (19.4)

 

36 (24.3)

10 (21.7)

 

FISH analysis, n (%)e

Yes

377 (59.8)

136 (52.5)

 

157 (38.4)

67 (34.2)

 

 Abnormalities foundf

281 (74.5)

99 (72.8)

 

116 (73.9)

44 (65.7)

 

  del(11q)

64 (17.0)

26 (19.1)

 

31 (19.7)

14 (20.9)

 

  del(13q)

179 (47.5)

59 (43.4)

 

69 (43.9)

30 (44.8)

 

  Trisomy 12

74 (19.6)

31 (22.8)

 

38 (24.2)

10 (14.9)

 

  del(17p)

33 (8.8)

18 (13.2)

 

28 (17.8)

9 (13.4)

 

  Other

24 (6.4)

14 (10.3)

 

11 (7.0)

6 (9.0)

 

 ALC (×109/L)

263

106

 

179

79

 

  Mean (×109/L)

68.5

58.4

 

52.7

54.2

 

  SD

75.7

62.9

 

64.5

51.9

 

  Median (×109/L)

46.1

34.6

 

25.6

40.1

 

  Range (×109/L)

0–564.0

1.3–275.4

 

0.1–306.0

0.8–271.1

 
  1. a p values (bold text) calculated using a Chi-square test. b p values of interest are shown. cData are missing. dRounding of numbers may cause totals to be =, <, or > 100%. eMore than one answer permitted. fPercentages calculated based on the number of patients tested
  2. ALC absolute lymphocyte count, CLL chronic lymphocytic leukemia, ECOG Eastern Cooperative Oncology Group, FISH fluorescence in-situ hybridization, HMO health maintenance organization, LOT1 first line of therapy, LOT ≥ 2 second line of therapy or greater, PPO preferred provider organization, SD standard deviation
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us